NCT Number: NCT00063102
A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with breast cancer after having had taxol or taxotere. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
Female
Study type
Interventional
Phase
Phase 2
Primary location
Oncology-Hematology Group of South Florida, Miami, Florida, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Stage IIIB or IV breast cancer.
- Recurrent tumor after or while on taxane therapy (taxol or taxotere).
- Able to tolerate normal activities of daily living.
- Adequate bone marrow, kidney and liver function.
Exclusion criteria
- Pregnant or breast feeding.
- No anti-tumor therapy (including hormonal therapy or Herceptin) within 4 weeks of the start of ABT-751 administration.
Treatment and study plan
Primary outcomes
-
Objective Response Rate in subjects with Breast cancer
Time frame: 1 year
Secondary outcomes
-
Time to Tumor Progression (TTP)
Time frame: 1 year
-
Survival
Time frame: 2 years
-
Toxicities associated with treatment administration
Time frame: 1 year
Sponsors and collaborators
Lead sponsor
Abbott
Industry
Registry information
Official study title
A Phase II Study of ABT-751 in Patients With Breast Cancer Refractory to Taxane Regimens
Important dates
- Study start
- 2002
- Study completion
- 2004
- First posted
- Jun 23, 2003
- Registry last updated
- Nov 29, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAfrican Cancer Genome: GMD
NCT05754658
Breast Cancer, Breast Diseases
Philadelphia, Pennsylvania, United States
View Trial Details24GUT540 : Meeting of Breast Cancer Patients and Pathologists
NCT07040514
Breast Cancer, Breast Diseases
Lebanon, New Hampshire, United States
View Trial DetailsNeoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
NCT06604858
Breast Cancer, Breast Diseases
A Coruña, Spain
View Trial Details